Compare ANGI & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | HELP |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.7M | 249.0M |
| IPO Year | 2017 | N/A |
| Metric | ANGI | HELP |
|---|---|---|
| Price | $6.84 | $5.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $17.00 | ★ $95.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-05-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $736,386,000.00 | N/A |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | $7.29 | ★ N/A |
| Revenue Growth | ★ 47.60 | N/A |
| 52 Week Low | $6.43 | $4.29 |
| 52 Week High | $19.42 | $8.55 |
| Indicator | ANGI | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 46.84 |
| Support Level | N/A | $4.41 |
| Resistance Level | $8.19 | $7.28 |
| Average True Range (ATR) | 0.39 | 0.32 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 23.86 | 85.57 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.